Amneal Shares Drop 6.3% After Q4 Beat But Lowers 2026 Revenue Forecast
Amneal Pharmaceuticals reported Q4 sales of $814.3 million, up 11.5% year-over-year, and adjusted earnings of $0.21 per share, both beating consensus. Full-year 2026 revenue guidance midpoint of $3.1 billion fell 3.4% short of analysts’ projections, triggering a 6.3% share price decline.
1. Q4 Financial Results
Amneal posted fourth-quarter sales of $814.3 million, an 11.5% increase year-over-year, and delivered adjusted earnings of $0.21 per share, both surpassing market expectations.
2. 2026 Revenue Guidance Miss
The company set 2026 revenue guidance midpoint at $3.1 billion, falling 3.4% below analysts’ forecasts and raising investor concerns about growth prospects.
3. Stock Reaction and Volatility
Shares plunged 6.3% in the afternoon session, marking one of only six moves over 5% in the past year, as the outlook miss overshadowed quarterly beats.
4. Performance Metrics
Year-to-date, Amneal is up 8.1% but remains 9.9% below its 52-week high; a $1,000 investment five years ago would now be worth $2,642.